Instrument overview

BRKRBruker Corp

StockNasdaqUnited StatesHealth careEU retail investors: available

+8.5% today · +67.3% over a year

4/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 47% of the instruments we score

Dividend yield 0.30%.

Bruker Corp (BRKR) belongs to the Health care sector and is listed on Nasdaq; country: United States. Its market value is about €9.1B. Over the past 12 months the price changed by +67.3%, with an annualised volatility of 60% and a largest fall of 40%. The dividend has not been lowered for 10 years.

Balanced 4/104/10Balanced
Weights for long-horizon accumulation: more quality and trend, no dividend requirement. These are three ways to weigh the same factors, not three properties of the instrument; Income compares within the sector, so a low yield can still score high. More in the glossary →4/10
Default weights: value, quality, trend, stability and dividend safety together. These are three ways to weigh the same factors, not three properties of the instrument; Income compares within the sector, so a low yield can still score high. More in the glossary →4/10
Weights for income: dividend safety counts most; shown for dividend payers only. These are three ways to weigh the same factors, not three properties of the instrument; Income compares within the sector, so a low yield can still score high. More in the glossary →1/10

The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.

Compared with: Health care companies in USA (n = 338)

Current rating first published: · last recomputed · rating log

Factor scores

How cheap the company is versus peers: earnings, cash flow, book value and sales relative to its price. More in the glossary →better than 47% of peers
Profitability, balance-sheet safety, growth and capital discipline versus peers. More in the glossary →better than 44% of peers
Price trend over the last 12 and 6 months (excluding the last month) and distance from the 52-week high. More in the glossary →better than 78% of peers
Lower price swings, lower market sensitivity (beta) and shallower drawdowns score higher. More in the glossary →better than 36% of peers
0–100 points: payout versus earnings and cash flow, debt, cut history, years without a lower dividend and how stretched the yield looks. More in the glossary →better than 67% of peers

Percentiles within the peer group (100 = the best of its peers); dividend safety in points.

Main drivers

  • Price / 52-week highsupports the score · better than 93% of peers
  • 12-month trend (ex last month)supports the score · better than 67% of peers
  • Share issuance (1 y)supports the score · better than 65% of peers

Red flags and notes

  • Caution. Net debt above 4× EBITDA or interest cover below 2×. More in the glossary → Net debt above 4× EBITDA or interest cover below 2×.
  • Sources disagree Dividend or fundamental sources disagree beyond tolerance.

Our sources disagree or are incomplete for this instrument.

Price chart

Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.

Key metrics

Valuation

P/B
4.4
P/S
2.9
Free-cash-flow yield
2.4%
Market cap (EUR)
€9.1B

Profitability and debt

Return on equity
−5.2%
Return on invested capital
−1.7%
Gross margin
47.7%
Net debt / EBITDA
10.77

Dividends

Dividend yield
0.30%
5-year dividend growth (per year)
4.6%
Years without a lower dividend
10

Returns and risk

1 day
+8.5%
1 month
+13.1%
1 year
+67.3%
Volatility, 1 yr
60.0%
Max drawdown, 1 yr
−39.8%
Beta
1.10

Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.

Similar companies

Same sector and region, closest in market value.

GMEDGlobus Medical Inc8/100.0%−9.0%
MDGLMadrigal Pharmaceuticals Inc1/100.0%−11.5%
SYRESpyre Therapeutics Inc.—/100.0%384.0%
PODDInsulet Corp7/100.0%−53.2%
BIOBio-Rad Laboratories Inc4/100.0%27.1%
HSICHenry Schein10/100.0%23.0%
MOHMolina Healthcare Inc5/100.0%33.7%
ENSGEnsign Group Inc8/100.1%1.3%

News and filings

What the marks mean
  • FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
  • Media reportA headline from a named media outlet. We link to it and do not check it.
  • RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.

Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.

Score changes in the last 12 months

Every published rating and change, logged when it was published (EU Market Abuse Regulation).

Show the log: 3 entries
DateEventBalancedGrowth · IncomeWarningsPrice at publication
Rating change 3 → 4/10 4 · 1 — Available with Invest Pro
Rating change 2 → 3/10 3 · 1 removed: Payout above earnings Available with Invest Pro
First rating 2/10 2 · 1 Caution. Dividends exceed earnings or free cash flow. More in the glossary → Available with Invest Pro

Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.